TY  - JOUR
AU  - Haeckert, Jan
AU  - Roeh, Astrid
AU  - Karch, Susanne
AU  - Koeglsperger, Thomas
AU  - Hasan, Alkomiet
AU  - Papazova, Irina
TI  - Impact of Parkinson Medication on Neuropsychiatric and Neurocognitive Symptoms in Patients with Advanced Parkinson Disease Prior to Deep Brain Stimulation.
JO  - Pharmacopsychiatry
VL  - 58
IS  - 1
SN  - 0176-3679
CY  - Stuttgart [u.a.]
PB  - Thieme
M1  - DZNE-2025-00029
SP  - 5 - 13
PY  - 2025
AB  - This study evaluates the impact of Parkinson disease (PD) medication in advanced PD on neuropsychological performance, psychiatric symptoms, impulsivity and the quality of life. In the 4-year period 27 patients with advanced PD, scheduled for deep brain stimulation (DBS) surgery (N=27, mean age: 58.9±7.1, disease duration: 10.0 years±4.2) were examined preoperatively. We hypothesized that a high dosage of PD medication or current use of dopamine agonists affect cognitive functioning and psychiatric wellbeing.We performed two subgroup analyses with low versus high levodopa-equivalent Dosage (LED) medication and without versus with dopaminagonistic medication.The neuropsychological testing revealed significant differences in the verbal learn- and memory-test (VLMT) during the learning passage (U=36.500, Z=- 2.475, p=0.012) and in the subtest of the semantic fluency of Regensburg verbal fluency test (RWT) (t(25)=- 2.066, p=0.049) with better results for patients without dopaminagonistic medication. Pearson correlation analyses of LED in correlation with the clinical and cognitive dependent variables showed a significant higher PANSS total score in patients with higher LED medication (r=0.491, p=0.009). In addition, lower LED treatment was associated with significant higher scores in the impulsivity perseverance subtest (r=- 0.509, p=0.008).In conclusion, we found lower LEDs to be correlated with a better perseverance in the impulsivity test and additional treatment with a dopamine agonist influenced some verbal learning tasks and the PANSS total score in patients with advanced PD. This should be considered prior to DBS surgery.
KW  - Humans
KW  - Parkinson Disease: drug therapy
KW  - Parkinson Disease: psychology
KW  - Parkinson Disease: complications
KW  - Parkinson Disease: therapy
KW  - Deep Brain Stimulation
KW  - Male
KW  - Middle Aged
KW  - Female
KW  - Neuropsychological Tests
KW  - Aged
KW  - Antiparkinson Agents: therapeutic use
KW  - Quality of Life
KW  - Dopamine Agonists: therapeutic use
KW  - Levodopa: therapeutic use
KW  - Cognition: drug effects
KW  - Antiparkinson Agents (NLM Chemicals)
KW  - Dopamine Agonists (NLM Chemicals)
KW  - Levodopa (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:39572152
DO  - DOI:10.1055/a-2446-6877
UR  - https://pub.dzne.de/record/274048
ER  -